Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector

Merck & Co. and Eisai have submitted to the FDA an application for the approval of kidney cancer combo treatment Keytruda-Lenvima. Bristol-Myers Squibb’s Opdivo is currently the only immunotherapy approved for kidney cancer and has a market share nearing 50%. The application reflects the excellent results obtained by the combination in a Phase Ib/II trial conducted last year. Moreover, the two companies have a Phase III clinical trial underway, whose results are expected for the end of 2019.
(Source: Reuters)